Don't have an account yet?
You will need the following to complete your application:
Register Now
Rapidly differentiate between a viral and bacterial infection
Acist PDF Brochure
The ACIST CVi® Contrast Delivery System simplifies procedures and helps elevate patient care.
FebriDx® is a rapid, handheld fingerstick blood test that delivers results in just 10–12 minutes. It empowers clinicians to quickly distinguish between viral and bacterial respiratory infections, supporting faster treatment decisions. In a primary care study, 97% of tests yielded valid results — providing near real-time insights that improve patient care.
Trophon®3 is the only automated ultrasound probe high-level disinfection (HLD) device built on patented hydrogen peroxide (H2O2) mist technology, combined with integrated digital traceability. It delivers consistent patient protection across every ultrasound probe reprocessing cycle.
By measuring CRP and MxA together, FebriDx offers a unique dual-marker approach for greater diagnostic confidence. In emergency department settings, it demonstrated 87% sensitivity and 64% specificity for bacterial infections, with an NPV of 89%, helping clinicians rule out bacterial causes more effectively.
FebriDx is proven to influence real-world prescribing behavior. In one study, its use in primary care was associated with a 41% absolute reduction in antibiotic prescribing intentions (from 86% down to 45%) — with no increase in reconsultations. By delivering trusted insights across adult and paediatric populations, FebriDx supports:
Developed by Lumos Diagnostics, an ASX-listed healthcare company headquartered in Melbourne, FebriDx showcases the power of Australian innovation on the global stage. From local research to international adoption, it represents cutting-edge science driving the future of diagnostic stewardship — delivering fast, accurate, and trusted solutions to clinicians worldwide.
Regional Health Care Group — a leading medical distribution company across Australia and New Zealand — proudly partners with Lumos Diagnostics to make FebriDx accessible to healthcare providers throughout the region.